{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PhXA41&page=2", "query": { "intervention": "PhXA41", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PhXA41&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T01:32:01.693Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02059278", "title": "Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Open Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "T-2345", "type": "DRUG" }, { "name": "Xalatan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nephron Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2014-01", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 1, "location_summary": "El Paso, Texas", "locations": [ { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02059278" }, { "nct_id": "NCT04761705", "title": "Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ocular Hypertension", "Open Angle Glaucoma" ], "interventions": [ { "name": "JV-GL1", "type": "DRUG" }, { "name": "Latanoprost 0.005% Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "JeniVision, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2021-03-10", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761705" }, { "nct_id": "NCT02179008", "title": "Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Open-angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "DE-117 Low Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 Low/Middle Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 Middle Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 Middle/High Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 High Dose ophthalmic solution", "type": "DRUG" }, { "name": "latanoprost ophthalmic solution 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2014-06", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2018-04-18", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 14, "location_summary": "Chandler, Arizona • Artesia, California • Glendale, California + 11 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Artesia", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02179008" }, { "nct_id": "NCT03657797", "title": "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glaucoma, Open-Angle", "Hypertension, Ocular" ], "interventions": [ { "name": "NCX 470", "type": "DRUG" }, { "name": "Latanoprost 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicox Ophthalmics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 656, "start_date": "2018-08-01", "completion_date": "2019-08-23", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657797" }, { "nct_id": "NCT00698945", "title": "Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ocular Hypertension", "Open-Angle Glaucoma" ], "interventions": [ { "name": "Istalol and Optive", "type": "DRUG" }, { "name": "Alphagan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bp Consulting, Inc", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-06", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2008-12-04", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 1, "location_summary": "Petaluma, California", "locations": [ { "city": "Petaluma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698945" }, { "nct_id": "NCT01254370", "title": "Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glaucoma", "Ocular Hypertension", "Ocular Surface Disease" ], "interventions": [ { "name": "Latanoprost", "type": "DRUG" }, { "name": "Travatan Z", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen SAS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2010-11", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254370" }, { "nct_id": "NCT02829996", "title": "Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Open-Angle Glaucoma (POAG)", "Ocular Hypertension (OHT)" ], "interventions": [ { "name": "trabodenoson 6.0% / latanoprost 0.005% QD", "type": "DRUG" }, { "name": "trabodenoson 3.0% / latanoprost 0.005% QD", "type": "DRUG" }, { "name": "trabodenoson 6.0% / latanoprost 0.0025% QD", "type": "DRUG" }, { "name": "latanoprost 0.005% QD", "type": "DRUG" }, { "name": "latanoprost 0.0025% QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inotek Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2016-08-19", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 1, "location_summary": "Lexington, Massachusetts", "locations": [ { "city": "Lexington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02829996" }, { "nct_id": "NCT02014142", "title": "A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ocular Hypertension", "Open-Angle Glaucoma" ], "interventions": [ { "name": "Latanoprost Punctal Plug Delivery System (L-PPDS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2013-12", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 18, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Torrance", "state": "California" }, { "city": "Cape Coral", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02014142" }, { "nct_id": "NCT05165290", "title": "Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Elevated Intraocular Pressure" ], "interventions": [ { "name": "Latanoprost ophthalmic solution, 0.005%", "type": "DRUG" }, { "name": "TC-002 latanoprost ophthalmic solution, 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TearClear Corp", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2021-11-29", "completion_date": "2022-09", "has_results": false, "last_update_posted_date": "2022-05-25", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 20, "location_summary": "Garden Grove, California • Glendale, California • Mission Hills, California + 16 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Petaluma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05165290" }, { "nct_id": "NCT04630808", "title": "MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Open Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "NCX 470 0.1%", "type": "DRUG" }, { "name": "Latanoprost 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicox Ophthalmics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 696, "start_date": "2020-11-09", "completion_date": "2025-06-25", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-09-24T01:32:01.693Z", "location_count": 63, "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630808" } ] }